近日，哈尔滨医科大学附属第二医院（简称“哈医大二院”）心血管病医院院长、心内科主任于波教授和贾海波教授团队，在心血管领域顶级期刊European Heart Journal 《欧洲心脏杂志》在线发表了题为“Plaque erosion risk and JAK2 V617F variant”的研究论文。该研究首次证实，JAK2 ...

意义未明的克隆性造血（CHIP）是近年来发现的一种新型非传统心血管疾病危险因素，携带CHIP突变会使冠心病的发病风险增加约2倍。然而，CHIP基因中的JAK2 V617F突变虽然较为少见，却能增加10倍以上的冠心病风险。

Acquisition of the constitutively active Janus kinase 2 (JAK2)V617F mutation occurs in almost all patients with polycythaemia vera (PV) and in a significant number of patients with essential ...

研究人员在 JAK 2-V617F 小鼠模型中研究 Socs 2 对 pegIFNα 治疗 MPN 的影响，发现靶向 SOCS 2 可增效。

A panelist discusses how advances in JAK2 V617F and other molecular monitoring have enhanced their ability to assess ...

An expert discusses how advances in JAK V617F monitoring have improved the assessment of disease status and guided treatment decisions and how risk assessment tools have transformed the ability to ...

Importantly, the new study discovered that all major JAK2 mutation types—exon 12 (causing polycythemia vera), V617F (80% of all three types of MPN), and exon 16 (acute lymphoid leukemia ...

If you have the JAK2 V617F mutation, are aged 18-74 years old, do not smoke, do not have any known autoimmune disease, and attend medical checks at UAB regularly, you may be eligible for our study!

If you have the JAK2 V617F mutation, are aged 18-74 years old, do not smoke, do not have any known autoimmune disease, and attend medical checks at UAB regularly, you may be eligible for our study!